UK tribunal upholds CMA pharma collusion fine
The UK’s Competition Appeal Tribunal has confirmed the Competition and Markets Authority’s finding that Lexon colluded with rival drug suppliers to keep up prices of an antidepressant sold to the National Health Service.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.